Latest from Weill Cornell Sandra & Edward Meyer Cancer Center

Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).
Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.
In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.
Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).
A host of novel agents are on the horizon that could further improve the long-term outcomes experienced by patients with follicular lymphoma, particularly those with relapsed or refractory disease.
Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).
Publication Bottom Border
Border Publication